Formulation for administration of RNA

Patent metadata

Field	Value
Publication number	US-11318195-B2
Application number	US-201716314719-A
Country	US
Kind code	B2
Filing date	Jul 14, 2017
Priority date	Jul 15, 2016
Publication date	May 3, 2022
Grant date	May 3, 2022

Abstract

The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.

First claim

The invention claimed is:

1. An immunogenic composition for intramuscular administration of RNA comprising:
(a) single stranded RNA; and
(b) polyethylenimine
wherein the single stranded RNA and the polyethylenimine are present in polyplex particles and the molar ratio of the number of nitrogen atoms (N) in the polyethylenimine to the number of phosphor atoms (P) in the single stranded RNA (N:P ratio) is 2.0 to 15.0 and the z-average as of the polyplex particles is less than 150 nm.

2. The composition of claim 1 , wherein the composition can be used as a pharmaceutical.

3. The composition of claim 1 , wherein the molar ratio of the number of nitrogen atoms (N) in the polyethylenimine to the number of phosphor atoms (P) in the single stranded RNA (N:P ratio) is 6.0 to 12.0.

4. An immunogenic composition for intramuscular administration of RNA comprising:
(a) single stranded RNA; and
(b) polyethylenimine
wherein
the ionic strength is 50 mM or less;
the single stranded RNA and the polyethylenimine are present in polyplex particles;
the molar ratio of the number of nitrogen atoms (N) in the polyethylenimine to the number of phosphor atoms (P) in the single stranded RNA (N:P ratio) is 2.0 to 15.0; and
the z-average of the polyplex particles is less than 150 nm.

5. The composition of claim 4 , wherein the concentration of monovalent cationic ions is 25 mM or less and the concentration of divalent cationic ions is 20 μM or less.

6. The composition of claim 1 , wherein the polyethylenimine comprises the following general formula (I):

wherein
R is H, an acyl group or a group comprising the following general formula (II):

wherein R1 is H or a group comprising the following general formula (III):

n, m, and l are independently selected from integers from is 2 to 10; and
p is an integer, wherein the average molecular weight of the polymer is 1.5·10 2 to 10 7 Da.

7. The composition of claim 1 , wherein at least 92% of the N atoms in the polyethylenimine are protonatable.

8. The composition of claim 1 , wherein the composition further comprises one or more additives.

9. The composition of claim 8 , wherein the one or more additives are selected from the group consisting of buffering substances, saccharides, stabilizers, cryoprotectants, lyoprotectants, and chelating agents.

10. The composition of claim 9 , wherein the buffering substances comprise at least one substance selected from the group consisting of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-morpholino-2-hydroxypropanesulfonic acid (MOPSO), acetic acid, acetate buffers and analogues, phosphoric acid and phosphate buffers, and citric acid, and citrate buffers.

11. The composition of claim 9 , wherein the saccharides comprise at least one saccharides selected from the group consisting of monosaccharides, disaccharides, trisaccharides, oligosaccharides, and polysaccharides.

12. The composition of claim 9 , wherein the cryoprotectants comprise at least one cryoprotectant selected from the group consisting of glycols, ethylene glycol, propylene glycol, and glycerol.

13. The composition of claim 9 , wherein the chelating agent comprises EDTA.

14. The composition of claim 9 , wherein the lipids comprise at least one lipid selected from the group consisting of cationic lipids, neutral lipids, and anionic lipids.

15. The composition of claim 1 , wherein the composition comprises HEPES buffered glucose (HBG) or HEPES buffered trehalose (HBT).

16. The composition of claim 1 , wherein the polydispersity index as derived from dynamic light scattering measurements of the polyplex particles is less than 0.5.

17. The composition of claim 1 , wherein the Zeta-potential of the polyplex particles is 20 mV or more.

18. The composition of claim 15 , wherein the HBG comprises 5% glucose (w/v) and 10 mM HEPES, pH 7.1.

19. The composition of claim 15 , wherein the HBT comprises 10% trehalose (w/v) and 10 mM HEPES, pH 7.1.

20. The composition of claim 1 , wherein the polyplex particles are neutral or positively charged at physiological pH.

21. The composition of claim 1 , wherein the single stranded RNA is a molecule of 6000 to 15000 bases.

22. The composition of claim 1 , wherein the single stranded RNA encodes at least one protein of interest.

23. The composition of claim 1 , wherein the single stranded RNA is a replicon.

24. The composition of claim 23 , wherein the replicon can be replicated by a replicase from an alphavirus, and wherein the replicon comprises a 5′ replication recognition sequence from an alphavirus, or a variant thereof, and a 3′ replication recognition sequence from an alphavirus, or a variant thereof.

25. The composition of claim 1 , wherein the single stranded RNA comprises an open reading frame encoding a peptide or protein of interest.

26. The composition of claim 1 , wherein the composition is formulated for use in therapy.

27. The composition of claim 1 , wherein the composition is a vaccine composition.

28. A method of administering the composition of claim 1 to a patient in need thereof, said method comprising parenterally administering the composition to the patient.

29. The method according to claim 28 , wherein administering the composition of claim 1 comprises intramuscularly administering the composition to the patient.

30. A method of intramuscular administration of RNA said method comprising the step of selecting a patient in need thereof and intramuscularly administering the composition of claim 1 .

31. A frozen, lyophilized or spray dried immunogenic composition for intramuscular administration of RNA comprising:
(a) single stranded RNA; and
(b) polyalkyleneimine
wherein the composition comprises a cryoprotectant and/or lyoprotectant, and the single stranded RNA and the polyethylenimine are present in polyplex particles and the molar ratio of the number of nitrogen atoms (N) in the polyethylenimine to the number of phosphor atoms (P) in the single stranded RNA (N:P ratio) is 2.0 to 15.0 and the z-average as of the polyplex particles is less than 150 nm.

32. The composition of claim 31 further comprising a chelating agent such as EDTA.

33. The composition of claim 31 which is prepared from an aqueous composition comprising a disaccharide at 5-20% (w/v) and optionally a chelating agent at 80 μM to 10 mM.

34. The composition of claim 33 wherein the aqueous composition comprises trehalose, HEPES, and EDTA.

35. An aqueous composition obtainable by thawing the frozen composition or reconstituting the lyophilized or spray dried composition of claim 31 .

36. A method of preparing a frozen, lyophilized or spray dried composition comprising:
(i) preparing an aqueous composition comprising single stranded RNA, polyalkyleneimine and a cryoprotectant and/or lyoprotectant,
wherein the single stranded RNA and the polyethylenimine are present in polyplex particle

Assignees

• Biontech Rna Pharmaceuticals Gmbh
• Tron—Translationale Onkologie An Der Univ Der Johannes Gutenberg
• BioNTech SE
• Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh

Inventors

• Sahin Ugur
• Haas Heinrich
• Vogel Annette
• Zucker Daniel
• Erbar Stephanie
• Walzer Kerstin
• Schlegel Anne
• Hörner Sebastian
• Kreiter Sebastian
• Diken Mustafa
• Moreno Herrero Jorge

Classifications

• A61K9/0019 Primary

  Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

• A61K39/12 Primary

  Viral antigens · CPC title

• A61K31/7105

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• C12N15/87

  Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation · CPC title

• A61P37/04

  Immunostimulants · CPC title